| Cvs Pharmacy #01433 | |
| 5922 Martin Luther King Jr Hwy, Seat Pleasant, Maryland 20743 | |
| (301) 925-8151 |
| Name | Cvs Pharmacy #01433 |
|---|---|
| Organization Name | Maryland Cvs Pharmacy Llc. |
| Location | 5922 Martin Luther King Jr Hwy, Seat Pleasant, Maryland 20743 |
| Type | Supplier |
| Phone | (301) 925-8151 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Genta Incorporated today announced that the Company has initiated a new Phase 2b clinical trial of tesetaxel as 1st-line chemotherapy for women with metastatic breast cancer. Tesetaxel is the leading oral taxane currently in clinical development. The new trial will be conducted at Memorial Sloan-Kettering Cancer Center, New York, NY and at the Accelerated Community Oncology Research Network (ACORN) based in Memphis, TN.
The new tools rely heavily on data to figure out just what it will cost to treat a patient - and they're sometimes buying information from "data brokers" to do it.
Mylan N.V. today announced the U.S. launch of Norethindrone and Ethinyl Estradiol Tablets (Chewable) 0.8 mg/0.025 mg and Ferrous Fumarate Tablets, 75 mg (Chewable), which is the generic version of Warner Chilcott's Generess Fe Tablets.
The Joint Commission has certified UT Southwestern University Hospital - St. Paul as a Primary Stroke Center, a distinction for hospitals fostering specialized stroke care for patients.
BerGenBio AS today announced the start of a Phase 1 Clinical Trial for BGB324, a first-in-class small molecule inhibitor of AXL tyrosine kinase. BGB324 is a highly selective, oral AXL inhibitor that blocks the epithelial-mesenchymal transition (EMT), which is a key driver of metastasis (cancer spread) and drug-resistance. The Phase 1 clinical trial of BGB324 is a single ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB324.
› Verified 8 days ago
News Archive
Genta Incorporated today announced that the Company has initiated a new Phase 2b clinical trial of tesetaxel as 1st-line chemotherapy for women with metastatic breast cancer. Tesetaxel is the leading oral taxane currently in clinical development. The new trial will be conducted at Memorial Sloan-Kettering Cancer Center, New York, NY and at the Accelerated Community Oncology Research Network (ACORN) based in Memphis, TN.
The new tools rely heavily on data to figure out just what it will cost to treat a patient - and they're sometimes buying information from "data brokers" to do it.
Mylan N.V. today announced the U.S. launch of Norethindrone and Ethinyl Estradiol Tablets (Chewable) 0.8 mg/0.025 mg and Ferrous Fumarate Tablets, 75 mg (Chewable), which is the generic version of Warner Chilcott's Generess Fe Tablets.
The Joint Commission has certified UT Southwestern University Hospital - St. Paul as a Primary Stroke Center, a distinction for hospitals fostering specialized stroke care for patients.
BerGenBio AS today announced the start of a Phase 1 Clinical Trial for BGB324, a first-in-class small molecule inhibitor of AXL tyrosine kinase. BGB324 is a highly selective, oral AXL inhibitor that blocks the epithelial-mesenchymal transition (EMT), which is a key driver of metastasis (cancer spread) and drug-resistance. The Phase 1 clinical trial of BGB324 is a single ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB324.
› Verified 8 days ago
Cvs Pharmacy # 01506 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 6200 Central Avenue, Seat Pleasant, Maryland 20743 Phone: (301) 350-8008 | |
Cvs Pharmacy #01433 Type: Medicare Supplier Location: 5922 Martin Luther King Jr Hwy, Seat Pleasant, Maryland 20743 Phone: (301) 925-8151 |